OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
Inhaled bacille Calmette–Guérin (BCG) provides a controlled human model to interrogate anti-mycobacterial immunity at defined time points, something not feasible in natural Mycobacterium tuberculosis infection. It also represents a promising mucosal vaccination route that outperforms intradermal (ID) BCG in animal models. We will present updated findings from two clinical trials in healthy adults: BCG-naïve and historically BCG-vaccinated participants received aerosolised BCG, with control groups of BCG-naïve participants given inhaled saline and previously vaccinated participants given ID BCG. Lung mucosal and peripheral blood responses were characterised longitudinally using single-cell RNA sequencing (scRNA-seq) and bulk T-cell receptor (TCR) sequencing.
